Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137 |
Type de publication | Journal Article |
Year of Publication | 2019 |
Auteurs | Amoureux L, Sauge J, Sarret B, Lhoumeau M, Bajard A, Tetu J, Bador J, Neuwirth C, Caillon J, Cardot-Martin E, Cattoir V, Doleans-Jordheim A, Ferroni A, Guet-Revillet H, Hery-Arnaud G, Segonds C, Thomas E, Plesiat P, Vu-Thien H, Grp MM |
Journal | JOURNAL OF CYSTIC FIBROSIS |
Volume | 18 |
Pagination | 804-807 |
Date Published | NOV |
Type of Article | Article |
ISSN | 1569-1993 |
Mots-clés | Achromobacter, Cystic fibrosis, Identification, MLST, nrdA, Resistance, ST 137 |
Résumé | We previously reported the distribution of Achromobacter spp. (species and Sequence Types (ST)) in our French Cystic Fibrosis (CF) centre. In the present study we collected 109 Achromobacter isolates (1/patient) from 9 other French CF Centres for species identification, antimicrobial susceptibility testings and Multilocus-Sequence-Typing (MLST) analysis. Ten species were detected, A. xylosoxidans being the most predominant one (73.4% of the isolates). Piperacillin-tazobactam, ceftazidime, imipenem, meropenem and ciprofioxacin were respectively active against 88, 70, 79, 72 and 23% of the isolates. Among the 79 A. xylosoxidans isolates, 46 STs were detected. Interestingly, ST 137, recovered in 4 centres (5 patients), was previously detected in our centre (2 patients). The strains from the 7 patients belonged to the same pulsotype (pulsed-field-gel-electrophoresis analysis) and harboured acquired resistance to meropenem, ceftazidime, ciprofioxacin, and except for 2 isolates, to imipenem and piperacillin-tazobactam. This is the first description in France of a circulating multiresistant A. xylosoxidans strain. (C) 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. |
DOI | 10.1016/j.jcf.2019.04.005 |